This report is a series of four post-launch reports that evaluates the trial and usage of XELJANZ (tofacitinib) among rheumatologists for the treatment of rheumatoid arthritis (RA).
LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products at one month, three months, six months and one year post launch. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and change market dynamics. They provide information on awareness, familiarity, and perceived clinical advantages and disadvantages of new products.

Questions Answered in This Report:

  • Evaluate awareness (aided/unaided), interest, and initial reaction to XELJANZ


  • Identify the expected placement of XELJANZ in physicians’ treatment algorithm for RA
    - How will it compete against the biologic agents?
    - Which class of biologic agents will be affected more—TNF inhibitors or the alternate mechanism of action agents?
    - How many biologic failures will it take for a physician to initiate XELJANZ treatment?

  • Track the trial, adoption and usage of XELJANZ, including anticipated future trends
    - What are the obstacles to growth for XELJANZ?

  • Determine what messages (and counter messages) are being delivered for XELJANZ
    - How will the product be positioned against the biologics?

  • Quantify the proportion of rheumatologists who have prescribed XELJANZ and at what point non-prescribers will begin initiating trial

Scope:

Sample Methodology:

~75-100 rheumatologists complete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, 15 surveyed specialists (ten specialists in Wave 5) participate in a 30-minute qualitative interview.

To qualify, respodents must meet the following criteria:

- Minimum of 100 patients with RA under their personal management

- Minimum of 50 RA patients treated with biologic agents/Xeljanz under their management

- Have been in practice a minimum of two years and a maximum of 35 years

- More than 75 percent of professional time spent in clinical practice

Deliverables:

PowerPoint decks to be published for each of four waves

Complete set of frequency tables, summary statistics, and cross tabulations

Up to three proprietary questions answered per client

Key Drugs Covered:

Actemra, Cimzia, Enbrel, Humira, Orencia IV/SC, Remicade, Rituxan, Simponi IV/SC, Xeljanz, baricitinib, sarilumab, secukinumab, sirukumab

Key Companies Mentioned:

AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Genentech, Janssen Biotech, Pfizer, and UCB Pharmaceuticals

Related Reports:

DecisionBase®: Rheumatoid Arthritis

Pharmacor®: Rheumatoid Arthritis

European Physician & Payer Forum®: Rheumatoid Arthritis

US Physician & Payer Forum®: Rheumatoid Arthritis

Treatment Algorithms®: Rheumatoid Arthritis

TreatmentTrends®: Rheumatoid Arthritis (US)

TreatmentTrends®: Rheumatoid Arthritis (EU)


Related Reports

Rheumatoid Arthritis | Landscape & Forecast | Disease Landscape & Forecast

The increasingly crowded RA market boasts many different targeted agents representing several distinct drug classes, including blockbuster

View Details

Rheumatoid Arthritis | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, together with conventional treatments...

View Details

Rheumatoid Arthritis | Emerging Therapies | Olumiant (Baricitinib) Launch Tracking Wave 3

Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after the launch of Pfizer’s Jak inhibito...

View Details

Rheumatoid Arthritis | Epidemiology | Emerging Markets

DRG Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key p...

View Details